Prognostic value of tumor markers ProGRP, NSE and CYFRA 21-1 in patients with small cell lung cancer and chemotherapy-induced remission.

Q3 Biochemistry, Genetics and Molecular Biology Tumor Biology Pub Date : 2024-01-01 DOI:10.3233/TUB-230016

Thomas Muley, Felix J Herth, Claus Peter Heussel, Mark Kriegsmann, Michael Thomas, Michael Meister, Marc A Schneider, Birgit Wehnl, Anika Mang, Stefan Holdenrieder

{"title":"Prognostic value of tumor markers ProGRP, NSE and CYFRA 21-1 in patients with small cell lung cancer and chemotherapy-induced remission.","authors":"Thomas Muley, Felix J Herth, Claus Peter Heussel, Mark Kriegsmann, Michael Thomas, Michael Meister, Marc A Schneider, Birgit Wehnl, Anika Mang, Stefan Holdenrieder","doi":"10.3233/TUB-230016","DOIUrl":null,"url":null,"abstract":"Background: Despite successful response to first line therapy, patients with small-cell lung cancer (SCLC) often suffer from early relapses and disease progression.Objective: To investigate the relevance of serum tumor markers for estimation of prognosis at several time points during the course of disease.Methods: In a prospective, single-center study, serial assessments of progastrin-releasing peptide (ProGRP), neuron-specific enolase (NSE), cytokeratin-19 fragments (CYFRA 21-1) and carcino-embryogenic antigen (CEA) were performed during and after chemotherapy in 232 SCLC patients, and correlated with therapy response and overall survival (OS).Results: ProGRP, NSE and CYFRA 21-1 levels decreased quickly after the first chemotherapy cycle and correlated well with the radiological response. Either as single markers or in combination they provided valuable prognostic information regarding OS at all timepoints investigated: prior to first-line therapy, after two treatment cycles in patients with successful response to first-line therapy, and prior to the start of second-line therapy. Furthermore, they were useful for continuous monitoring during and after therapy and often indicated progressive disease several months ahead of radiological changes.Conclusions: The results indicate the great potential of ProGRP, NSE and CYFRA 21-1 for estimating prognosis and monitoring of SCLC patients throughout the course of the disease.","PeriodicalId":23364,"journal":{"name":"Tumor Biology","volume":" ","pages":"S219-S232"},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tumor Biology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3233/TUB-230016","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Biochemistry, Genetics and Molecular Biology","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Despite successful response to first line therapy, patients with small-cell lung cancer (SCLC) often suffer from early relapses and disease progression.

Objective: To investigate the relevance of serum tumor markers for estimation of prognosis at several time points during the course of disease.

Methods: In a prospective, single-center study, serial assessments of progastrin-releasing peptide (ProGRP), neuron-specific enolase (NSE), cytokeratin-19 fragments (CYFRA 21-1) and carcino-embryogenic antigen (CEA) were performed during and after chemotherapy in 232 SCLC patients, and correlated with therapy response and overall survival (OS).

Results: ProGRP, NSE and CYFRA 21-1 levels decreased quickly after the first chemotherapy cycle and correlated well with the radiological response. Either as single markers or in combination they provided valuable prognostic information regarding OS at all timepoints investigated: prior to first-line therapy, after two treatment cycles in patients with successful response to first-line therapy, and prior to the start of second-line therapy. Furthermore, they were useful for continuous monitoring during and after therapy and often indicated progressive disease several months ahead of radiological changes.

Conclusions: The results indicate the great potential of ProGRP, NSE and CYFRA 21-1 for estimating prognosis and monitoring of SCLC patients throughout the course of the disease.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

肿瘤标志物ProGRP、NSE和CYFRA 21-1对小细胞肺癌癌症和化疗诱导的缓解患者的预后价值。

背景：尽管一线治疗取得了成功，但癌症小细胞肺癌（SCLC）患者往往会出现早期复发和疾病进展。目的：探讨血清肿瘤标志物在疾病过程中几个时间点对预后评估的相关性。方法：在一项前瞻性的单中心研究中，对232例SCLC患者化疗期间和化疗后的前胃泌素释放肽（ProGRP）、神经元特异性烯醇化酶（NSE）、细胞角蛋白-19片段（CYFRA 21-1）和癌胚性抗原（CEA）进行了一系列评估，并与治疗反应和总生存率（OS）相关，NSE和CYFRA 21-1水平在第一个化疗周期后迅速下降，并与放射反应良好相关。无论是作为单一标志物还是组合，它们都在所研究的所有时间点提供了关于OS的有价值的预后信息：在一线治疗之前，在对一线治疗有成功反应的患者的两个治疗周期之后，以及在二线治疗开始之前。此外，它们有助于在治疗期间和治疗后进行持续监测，通常在放射学变化前几个月表明疾病进展。结论：ProGRP、NSE和CYFRA 21-1在评估SCLC患者的预后和监测整个疾病过程中具有巨大的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Tumor Biology 医学-肿瘤学

CiteScore

5.40

自引率

0.00%

发文量

审稿时长

1 months

期刊介绍： Tumor Biology is a peer reviewed, international journal providing an open access forum for experimental and clinical cancer research. Tumor Biology covers all aspects of tumor markers, molecular biomarkers, tumor targeting, and mechanisms of tumor development and progression. Specific topics of interest include, but are not limited to: Pathway analyses, Non-coding RNAs, Circulating tumor cells, Liquid biopsies, Exosomes, Epigenetics, Cancer stem cells, Tumor immunology and immunotherapy, Tumor microenvironment, Targeted therapies, Therapy resistance Cancer genetics, Cancer risk screening. Studies in other areas of basic, clinical and translational cancer research are also considered in order to promote connections and discoveries across different disciplines. The journal publishes original articles, reviews, commentaries and guidelines on tumor marker use. All submissions are subject to rigorous peer review and are selected on the basis of whether the research is sound and deserves publication. Tumor Biology is the Official Journal of the International Society of Oncology and BioMarkers (ISOBM).